TWi Pharmaceuticals

1 2

/ Press Releases: 2015.01; TWi Confirms Patent Challenge Relating to Oxtellar XR®, Oxcarbazepine ER Tablet; 2014.12; TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China; 2014.12; TWi Biotechnology receives approval of protocol for its drug AC-201 Controlled-Release Tablet, Phase II clinical trial in both the United States and Taiwan; 2014.10; TWi Pharmaceuticals Receives US FDA Approval on Generic Donepezil Hydrochloride Tablets USP, 23 mg, its fifth ANDA from US FDA; 2014.10; TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 in United States.